JNJ | Weekly | Haru Insights

The FDA De Novo approval of Johnson & Johnson’s OTTAVA robotic surgery platform marks a transformative milestone, positioning JNJ as a direct challenger to Intuitive Surgical in the $10 billion+ surgical robotics market—a first major entry into this high-growth space.
The proposed $5.5 billion talc settlement framework has gained judicial momentum, with recent skepticism toward key plaintiff testimonies and disqualification of a major law firm, signaling a potential turning point in JNJ’s decades-long legal saga and boosting institutional confidence.

OTTAVA’s FDA De Novo approval is a bold, credible leap into surgical robotics, leveraging a compact design and early market entry to disrupt Intuitive Surgical’s dominance—proving JNJ’s innovation muscle is alive and well.
JNJ’s robust Q2 2026 results, including a beat on earnings and sales, a guidance raise, and 8.9% adjusted EPS growth, reflect strong execution and confidence in its diversified pipeline.
The $5.5 billion talc settlement, if approved, could finally extinguish a decades-long overhang, unlocking shareholder value and enabling strategic reinvestment in high-growth areas.
JNJ’s 64-year dividend growth streak, AAA credit rating, and rising institutional backing—from Balyasny, Citadel, and Fisher—signal enduring market trust and a re-rating potential amid strong fundamentals.
Explosive growth from CARVYKTI, Tremfya, and Darzalex, alongside strong organic sales gains and new product launches, confirms a powerful pipeline transition beyond Stelara’s patent cliff.

Johnson & Johnson (JNJ)[Tv]